VNDA (Vanda Pharmaceuticals Inc.) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Vanda Pharmaceuticals develops therapies for severe mental pathologies, leveraging FDA-approved exclusive dosing regimens. Despite physician confidence, investors are deterred by the business's legal instability. This EV/EBITDA chart illustrating valuation trends shows a value of 0.00, while risks stem from pressure from biotech behemoths and the struggle for narrow market niches within the sleep medication segment.

VNDA (Vanda Pharma) Company Value to EBITDA history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for vandapharma.com (VNDA)

- market price and analyst price targets:

Price Chart Vanda Pharmaceuticals Inc|VNDA - Forecast Levels Chart

- business market valuation indicators:

Market Value Vanda|VNDA - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share Vanda Pharmaceuticals|VNDA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio vandapharma.com|VNDA - Cumulative Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

VNDA - Company Profit|Projected Future Earnings Vanda Pharmaceuticals|VNDA - Price to Earnings Multiple|Forward P/E Multiple Vanda Pharmaceuticals|VNDA - PEG Multiple|Enterprise Value to EBITDA Ratio Vanda|VNDA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Vanda Pharmaceuticals|VNDA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth vandapharma.com|VNDA - Earnings per share increase in current year|Earnings growth forecast for next year Vanda Pharmaceuticals

Initial company analysis:Vanda Pharmaceuticals Inc (VNDA)

Product sample of Vanda Pharmaceuticals Inc.

The EV/EBITDA ratio determines the total enterprise value, including debt, relative to its operating profit before interest, taxes, depreciation, and amortization. This metric allows an investor to objectively compare the asset values of different companies by neutralizing differences in capital structure. By analyzing the EV/EBITDA trend, one can identify points of historical asset undervaluation. For Vanda Pharmaceuticals (VNDA), this indicator is critical when assessing the sustainability of cash flows generated from the sale of defensive drugs in neuropsychiatry.

Who Vanda Pharmaceuticals competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|MNMD (MindMed) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bright Minds Corp (DRUG)|EV/EBITDA Multiple CYBN|ANRO (altoneuroscience.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRx Pharmaceuticals, Inc. NRXP|Cingulate Inc (CING) - Company Value to EBITDA|SILO: Enterprise Value to EBITDA Ratio|CPHI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CMND: EV/EBITDA Multiple|pacificbayminerals.com (PBM) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SciSparc|Enterprise Value to Operating Income Before Depreciation SEEL (Seelos Therapeutics Inc.)|EV/EBITDA Multiple VRPX|Karuna Pharma - Enterprise Value to Operating Income Before Depreciation